A wave of regulatory approvals particularly for cardiovascular disease signals broader therapeutic potential, and growing optimism extends to their use in areas such as neurodegenerative disorders and addiction medicine
stated, "Multiple [...] studies reported the role of IGF-1 in enhancing insulin sensitivity and glucose metabolism
However, these studies typically involved healthy volunteers or individuals with prediabetes rather than patients already receiving GLP-1 receptor agonist therapy, limiting direct applicability to the clinical question of combination benefits
DOSAGE Dosing for IGF-1 LR3 is based on anecdotal data and preclinical research, aiming for low-dose, infrequent administration due to the compound's potency and long half-life
According to him, tests were conclusive
doi: 10.1007/s00018-020-03536-5 27 BackertSNeddermannMMaubachGNaumannM